Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (}= 9 log(10) copies/ml)

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F15%3A00059260" target="_blank" >RIV/00023001:_____/15:00059260 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.readcube.com/articles/10.1111%2Fliv.12694?r3_referer=wol&tracking_action=preview_click&show_checkout=1&purchase_referrer=onlinelibrary.wiley.com&purchase_site_license=PUBLICATION_OUTSIDE_OF_LICENSE_PERIOD" target="_blank" >http://www.readcube.com/articles/10.1111%2Fliv.12694?r3_referer=wol&tracking_action=preview_click&show_checkout=1&purchase_referrer=onlinelibrary.wiley.com&purchase_site_license=PUBLICATION_OUTSIDE_OF_LICENSE_PERIOD</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/liv.12694" target="_blank" >10.1111/liv.12694</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (}= 9 log(10) copies/ml)

Popis výsledku v původním jazyce

Background & AimsWe evaluated the antiviral response of Asian or Pacific Islander (API) patients with chronic hepatitis B (CHB) who had baseline high viral load (HVL), defined as pre-treatment hepatitis B virus (HBV) DNA 9 log(10) copies/ml, following up to 288weeks of tenofovir disoproxil fumarate (TDF) treatment. MethodsA total of 205 HBeAg-negative and HBeAg-positive self-described API patients received 48weeks of TDF 300mg (HVL n=18) or adefovir dipivoxil 10mg (HVL n=15) in a blinded fashion, followed by open-label TDF for an additional 240weeks. The proportions of HVL vs. non-HVL patients with HBV DNA <400 copies/ml were compared. Mean declines in HBV DNA were evaluated in API vs. non-API patients. ResultsThroughout the first 72weeks of treatment, a smaller proportion of HVL API patients reached HBV DNA <400 copies/ml than non-HVL API patients. However, after this timepoint similar proportions of HVL and non-HVL API patients achieved HBV DNA <400 copies/ml (100% vs. 97%, respectively), which was maintained through week 288, where 92% of HVL patients and 99% of non-HVL API patients on treatment had HBV DNA <400 copies/ml. During the 288weeks of treatment, API patients had similar mean HBV DNA declines as non-API patients, regardless of whether patients were HVL or non-HVL. No API HVL patient had persistent viremia at week 288. No resistance was detected among HVL or non-HVL patients. ConclusionsAPI patients with HVL CHB achieve HBV DNA <400 copies/ml with long-term TDF treatment; however, achieving viral suppression may take longer for HVL patients relative to non-HVL API patients.

Název v anglickém jazyce

Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (}= 9 log(10) copies/ml)

Popis výsledku anglicky

Background & AimsWe evaluated the antiviral response of Asian or Pacific Islander (API) patients with chronic hepatitis B (CHB) who had baseline high viral load (HVL), defined as pre-treatment hepatitis B virus (HBV) DNA 9 log(10) copies/ml, following up to 288weeks of tenofovir disoproxil fumarate (TDF) treatment. MethodsA total of 205 HBeAg-negative and HBeAg-positive self-described API patients received 48weeks of TDF 300mg (HVL n=18) or adefovir dipivoxil 10mg (HVL n=15) in a blinded fashion, followed by open-label TDF for an additional 240weeks. The proportions of HVL vs. non-HVL patients with HBV DNA <400 copies/ml were compared. Mean declines in HBV DNA were evaluated in API vs. non-API patients. ResultsThroughout the first 72weeks of treatment, a smaller proportion of HVL API patients reached HBV DNA <400 copies/ml than non-HVL API patients. However, after this timepoint similar proportions of HVL and non-HVL API patients achieved HBV DNA <400 copies/ml (100% vs. 97%, respectively), which was maintained through week 288, where 92% of HVL patients and 99% of non-HVL API patients on treatment had HBV DNA <400 copies/ml. During the 288weeks of treatment, API patients had similar mean HBV DNA declines as non-API patients, regardless of whether patients were HVL or non-HVL. No API HVL patient had persistent viremia at week 288. No resistance was detected among HVL or non-HVL patients. ConclusionsAPI patients with HVL CHB achieve HBV DNA <400 copies/ml with long-term TDF treatment; however, achieving viral suppression may take longer for HVL patients relative to non-HVL API patients.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FE - Ostatní obory vnitřního lékařství

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Liver international

ISSN

1478-3223

e-ISSN

—

Svazek periodika

35

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

7

Strana od-do

422-428

Kód UT WoS článku

000348714500019

EID výsledku v databázi Scopus

—